<DOC>
	<DOC>NCT02776683</DOC>
	<brief_summary>The objective of this trial is to evaluate the safety and tolerability of BI 695502 in combination with leucovorin/5-fluorouracil/oxaliplatin (mFOLFOX6) and as maintenance therapy (when applicable). As well as to evaluate the following efficacy parameters: Progression-free survival (PFS), objective response rate (proportion of patients with complete response [CR] plus partial response [PR]), overall survival (OS), duration of response (DOR), time to progression (TTP).</brief_summary>
	<brief_title>Open-label, Single Arm Trial of BI 695502 in Patients With Previously Untreated Metastatic Colorectal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<criteria>Inclusion criteria: Males and females aged &gt;=18 years (for Japan only: Age &gt;=20 years at time of signing Informed Consent Form) with histologically confirmed metastatic colorectal cancer (mCRC). Metastatic disease not amenable to surgical curative treatment and eligible to receive therapy with mFOLFOX6 (Leucovorin/5Fluorouracil/Oxaliplatin) + bevacizumab. At least one measurable lesion according to Response Evaluation Criteria in Solid Tumors (RECIST) 1.1. Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1. Adequate hepatic, renal and bone marrow function. Further inclusion criteria apply. Exclusion criteria: Prior systemic therapy for metastatic disease Prior therapy with monoclonal antibodies or small molecule inhibitors against Vascular endothelial growth factor (VEGF) or VEGF receptors, including Avastin® or Avastin® biosimilar Previous malignancy other than Colorectal cancer (CRC) in the last 5 years except for basal cell cancer of the skin or preinvasive cancer of the cervix Spinal cord compression or brain metastases unless asymptomatic, stable and not requiring steroids for at least 6 weeks prior to start of study treatment Any unresolved toxicity &gt; Common Toxicity Criteria Grade 1 (except alopecia) from previous anticancer therapy (including radiotherapy) History or evidence of inherited bleeding diathesis or coagulopathy with the risk of bleeding A thrombotic or hemorrhagic event &lt;=6 months prior to screening (includes hemoptysis, Gastrointestinal (GI) bleeding, hematemesis, central nervous system hemorrhage, epistaxis, vaginal bleeding, cerebral infarction, transient ischemic attacks, myocardial infarction, angina, and coronary artery disease) Further exclusion criteria apply</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>